Statins, atherosclerosis regression and HDL: Insights from within the plaque

International Journal of Cardiology

Volumn 189, Issue 1, 2015, Pages 168-171

  Feig, Jonathan E ^a   Feig, Jessica L ^b   Kini, Annapoorna S ^a  

^a MOUNT SINAI HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; HDL; Near infrared spectroscopy; Optical coherence tomography; Regression

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MEGADOSE; GENE EXPRESSION; HEART INFARCTION; HUMAN; INFRARED SPECTROSCOPY; INTRAVASCULAR ULTRASOUND; MACROPHAGE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REMISSION; REVIEW; METABOLISM; NEAR INFRARED SPECTROSCOPY; PATHOLOGY; PROCEDURES;

ATHEROSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; ROSUVASTATIN CALCIUM; SPECTROSCOPY, NEAR-INFRARED; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84929162833     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.036     Document Type: Editorial

References (38)

1. D.H. Blankenhorn, H.N. Hodis, George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal, Arterioscler. Thromb. 14 (1994) 177-192.
2. K.J. Williams, J.E. Feig, E.A. Fisher, Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal, Curr. Opin. Lipidol. 18 (2007) 443-450.
3. K.J. Williams, J.E. Feig, E.A. Fisher, Rapid regression of atherosclerosis: insights from the clinical and experimental literature, Nat. Clin. Pract. Cardiovasc. Med. 5 (2008) 91-102.
4. M. Friedman, S.O. Byers, R.H. Rosenman, Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion, Proc. Soc. Exp. Biol. Med. 95 (1957) 586-588.
5. A. Miyazaki, S. Sakuma, W. Morikawa, T. Takiue, F. Miake, T. Terano, M. Sakai, H. Hakamata, Y. Sakamoto, M. Natio, et al, Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1882-1888.
6. E.D. Reis, J. Li, Z.A. Fayad, J.X. Rong, D. Hansoty, J.G. Aguinaldo, J.T. Fallon, E.A. Fisher, Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model, J. Vasc. Surg. 34 (2001) 541-547.
7. E. Trogan, Z.A. Fayad, V.V. Itskovich, J.G. Aguinaldo, V. Mani, J.T. Fallon, I. Chereshnev, E.A. Fisher, Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia, Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1714-1719.
8. E. Trogan, J.E. Feig, S. Dogan, G.H. Rothblat, V. Angeli, F. Tacke, G.J. Randolph, E.A. Fisher, Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3781-3786.
9. J.E. Feig, Regression of atherosclerosis: insights from animal and clinical studies, Ann. Glob. Health 80 (2014) 13-23.
10. J.E. Feig, J.L. Feig, Macrophages, dendritic cells, and regression of atherosclerosis, Front. Physiol. 3 (2012) 286.
11. J.E. Feig, B. Hewing, J.D. Smith, S.L. Hazen, E.A. Fisher, High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies, Circ. Res. 114 (2014) 205-213.
12. J.E. Feig, S. Parathath, J.X. Rong, S.L. Mick, Y. Vengrenyuk, L. Grauer, S.G. Young, E.A. Fisher, Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques, Circulation 123 (2011) 989-998.
13. J.E. Feig, I. Pineda-Torra, M. Sanson, M.N. Bradley, Y. Vengrenyuk, D. Bogunovic, E.L. Gautier, D. Rubinstein, C. Hong, J. Liu, C. Wu, N. van Rooijen, N. Bhardwaj, M. Garabedian, P. Tontonoz, E.A. Fisher, LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression, J. Clin. Invest. 120 (2010) 4415-4424.
14. J.E. Feig, J.S. Quick, E.A. Fisher, The role of a murine transplantation model of atherosclerosis regression in drug discovery, Curr. Opin. Investig. Drugs 10 (2009) 232-238.
15. J.E. Feig, J.X. Rong, R. Shamir, M. Sanson, Y. Vengrenyuk, J. Liu, K. Rayner, K. Moore, M. Garabedian, E.A. Fisher, HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 7166-7171.
16. J.E. Feig, R. Shamir, E.A. Fisher, Atheroprotective effects of HDL: beyond reverse cholesterol transport, Curr. Drug Targets 9 (2008) 196-203.
17. J.E. Feig, Y. Shang, N. Rotllan, Y. Vengrenyuk, C. Wu, R. Shamir, I.P. Torra, C. Fernandez-Hernando, E.A. Fisher, M.J. Garabedian, Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages, PLoS One 6 (2011) e28534.
18. J.E. Feig, Y. Vengrenyuk, V. Reiser, C. Wu, A. Statnikov, C.F. Aliferis, M.J. Garabedian, E.A. Fisher, O. Puig, Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome, PLoS One 7 (2012) e39790.
19. S.J. Nicholls, A. Hsu, K. Wolski, B. Hu, O. Bayturan, A. Lavoie, K. Uno, E.M. Tuzcu, S.E. Nissen, Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome, J. Am. Coll. Cardiol. 55 (2010) 2399-2407.
20. I.K. Jang, G.J. Tearney, B. MacNeill, M. Takano, F. Moselewski, N. Iftima, M. Shishkov, S. Houser, H.T. Aretz, E.F. Halpern, B.E. Bouma, In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography, Circulation 111 (2005) 1551-1555.
21. G.W. Stone, A. Maehara, A.J. Lansky, B. de Bruyne, E. Cristea, G.S. Mintz, R. Mehran, J. McPherson, N. Farhat, S.P. Marso, H. Parise, B. Templin, R. White, Z. Zhang, P.W. Serruys, A prospective natural-history study of coronary atherosclerosis, N. Engl. J. Med. 364 (2011) 226-235.
22. W. Jaross, V. Neumeister, P. Lattke, D. Schuh, Determination of cholesterol in atherosclerotic plaques using near infrared diffuse reflection spectroscopy, Atherosclerosis 147 (1999) 327-337.
23. P.R. Moreno, R.A. Lodder, K.R. Purushothaman, W.E. Charash, W.N. O'Connor, J.E. Muller, Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy, Circulation 105 (2002) 923-927.
24. J. Wang, Y.J. Geng, B. Guo, T. Klima, B.N. Lal, J.T. Willerson, W. Casscells, Near-infrared spectroscopic characterization of human advanced atherosclerotic plaques, J. Am. Coll. Cardiol. 39 (2002) 1305-1313.
25. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, T. Crowe, W.J. Sasiela, J. Tsai, J. Orazem, R.D. Magorien, C. O'Shaughnessy, P. Ganz, Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease, N. Engl. J. Med. 352 (2005) 29-38.
26. S.J. Nicholls, C.M. Ballantyne, P.J. Barter, M.J. Chapman, R.M. Erbel, P. Libby, J.S. Raichlen, K. Uno, M. Borgman, K. Wolski, S.E. Nissen, Effect of two intensive statin regimens on progression of coronary disease, N. Engl. J. Med. 365 (2011) 2078-2087.
27. L.A. Cassis, R.A. Lodder, Near-IR imaging of atheromas in living arterial tissue, Anal. Chem. 65 (1993) 1247-1256.
28. S. Waxman, S.R. Dixon, P. L'Allier, J.W. Moses, J.L. Petersen, D. Cutlip, J.C. Tardif, R.W. Nesto, J.E. Muller, M.J. Hendricks, S.T. Sum, C.M. Gardner, J.A. Goldstein, G.W. Stone, M.W. Krucoff, In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study, JACC Cardiovasc. Imaging 2 (2009) 858-868.
29. A.S. Kini, U. Baber, J.C. Kovacic, A. Limaye, Z.A. Ali, J. Sweeny, A. Maehara, R. Mehran, G. Dangas, G.S. Mintz, V. Fuster, J. Narula, S.K. Sharma, P.R. Moreno, Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy), J. Am. Coll. Cardiol. 62 (2013) 21-29.
30. D. Huang, E.A. Swanson, C.P. Lin, J.S. Schuman, W.G. Stinson, W. Chang, M.R. Hee, T. Flotte, K. Gregory, C.A. Puliafito, et al, Optical coherence tomography, Science 254 (1991) 1178-1181.
31. B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M.K. Jensen, G. Hindy, H. Holm, E.L. Ding, T. Johnson, H. Schunkert, N.J. Samani, R. Clarke, J.C. Hopewell, J.F. Thompson, M. Li, G. Thorleifsson, C. Newton-Cheh, K. Musunuru, J.P. Pirruccello, D. Saleheen, L. Chen, A. Stewart, A. Schillert, U. Thorsteinsdottir, G. Thorgeirsson, S. Anand, J.C. Engert, T. Morgan, J. Spertus, M. Stoll, K. Berger, N. Martinelli, D. Girelli, P.P. McKeown, C.C. Patterson, S.E. Epstein, J. Devaney, M.S. Burnett, V. Mooser, S. Ripatti, I. Surakka, M.S. Nieminen, J. Sinisalo, M.L. Lokki, M. Perola, A. Havulinna, U. de Faire, B. Gigante, E. Ingelsson, T. Zeller, P. Wild, P.I. de Bakker, O.H. Klungel, A.H. Maitland-van der Zee, B.J. Peters, A. de Boer, D.E. Grobbee, P.W. Kamphuisen, V.H. Deneer, C.C. Elbers, N.C. Onland-Moret, M.H. Hofker, C. Wijmenga, W.M. Verschuren, J.M. Boer, Y.T. van der Schouw, A. Rasheed, P. Frossard, S. Demissie, C. Willer, R. Do, J.M. Ordovas, G.R. Abecasis, M. Boehnke, K.L. Mohlke, M.J. Daly, C. Guiducci, N.P. Burtt, A. Surti, E. Gonzalez, S. Purcell, S. Gabriel, J. Marrugat, J. Peden, J. Erdmann, P. Diemert, C. Willenborg, I.R. Konig, M. Fischer, C. Hengstenberg, A. Ziegler, I. Buysschaert, D. Lambrechts, F. Van de Werf, K.A. Fox, N.E. El Mokhtari, D. Rubin, J. Schrezenmeir, S. Schreiber, A. Schafer, J. Danesh, S. Blankenberg, R. Roberts, R. McPherson, H. Watkins, A.S. Hall, K. Overvad, E. Rimm, E. Boerwinkle, A. Tybjaerg-Hansen, L.A. Cupples, M.P. Reilly, O. Melander, P.M. Mannucci, D. Ardissino, D. Siscovick, R. Elosua, K. Stefansson, C.J. O'Donnell, V. Salomaa, D.J. Rader, L. Peltonen, S.M. Schwartz, D. Altshuler, S. Kathiresan, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study, Lancet 380 (2012) 572-580.
32. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, W. Weintraub, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N. Engl. J. Med. 365 (2011) 2255-2267.
33. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R. Tall, B. Brewer, Effects of torcetrapib in patients at high risk for coronary events, N. Engl. J. Med. 357 (2007) 2109-2122.
34. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, J. Brumm, B.R. Chaitman, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, H. Mundl, S.J. Nicholls, P.K. Shah, J.C. Tardif, R.S. Wright, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N. Engl. J. Med. 367 (2012) 2089-2099.
35. G.G. Schwartz, A.G. Olsson, C.M. Ballantyne, P.J. Barter, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, P.K. Shah, J.C. Tardif, B.R. Chaitman, R. Duttlinger-Maddux, J. Mathieson, Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome, Am. Heart J. 158 (2009) 896-901.
36. M.J. Landray, R. Haynes, J.C. Hopewell, S. Parish, T. Aung, J. Tomson, K. Wallendszus, M. Craig, L. Jiang, R. Collins, J. Armitage, Effects of extended-release niacin with laropiprant in high-risk patients, N. Engl. J. Med. 371 (2014) 203-212.
37. A.V. Khera, M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M.F. Burke, K. Jafri, B.C. French, J.A. Phillips, M.L. Mucksavage, R.L. Wilensky, E.R. Mohler, G.H. Rothblat, D.J. Rader, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis, N. Engl. J. Med. 364 (2011) 127-135.
38. A. Rohatgi, A. Khera, J.D. Berry, E.G. Givens, C.R. Ayers, K.E. Wedin, I.J. Neeland, I.S. Yuhanna, D.R. Rader, J.A. de Lemos, P.W. Shaul, HDL cholesterol efflux capacity and incident cardiovascular events, N. Engl. J. Med. 371 (2014) 2383-2393.